Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer’s Sheds Light on Clinical Trial Exclusion Criteria
2017 ◽
Vol 6
(1)
◽
pp. 201-209
◽
2015 ◽
Vol 11
(8)
◽
pp. 986-993
◽
2019 ◽
Vol 15
(3)
◽
pp. 353
◽
Keyword(s):